Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
filingDate |
2018-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73a8d4cc16357235942e34e3fda3ffb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_575aa99b4a1b3d36d114015551396525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa94e4debd1ff1fff49b15bbdfffa5ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc15401a6b2dff5b235f2f79e18fbb24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61a3c23e4299885994f97926e4d35df5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c803dd01fa41c4a15f1e4e16210ebfb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f77266da024988b9c78e6b8ffa19d65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65ffefe2bb0532914c9d45f2a1d69ebd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaaa024eec59427699acaa88023d52fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ceba070752048340ff9a5b6d9aadd3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_690cf824ad030eb757f4f434066c3408 |
publicationDate |
2018-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2018256731-A1 |
titleOfInvention |
Novel insulin analog and use thereof |
abstract |
An insulin analog has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form for the purpose of increasing the blood half-life of insulin. A conjugate is prepared by linking the insulin analog and a carrier. A long-acting formulation includes the conjugate. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021022149-A1 |
priorityDate |
2013-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |